Get the Stockscreener App
19.51
0.36%
0.07
Pre-market:
19.42
-0.09
-0.46%
Innoviva Inc stock is traded at $19.51, with a volume of 898.26K.
It is up +0.36% in the last 24 hours and down -5.43% over the past month.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
See More
Previous Close:
$19.44
Open:
$19.62
24h Volume:
898.26K
Relative Volume:
1.06
Market Cap:
$1.46B
Revenue:
$384.03M
Net Income/Loss:
$38.65M
P/E Ratio:
62.94
EPS:
0.31
Net Cash Flow:
$196.35M
1W Performance:
+1.04%
1M Performance:
-5.43%
6M Performance:
+3.94%
1Y Performance:
+11.10%
1-Day Range:
$19.00
$19.62
1-Week Range:
$19.00
$20.04
52-Week Range:
$16.52
$22.76
Innoviva Inc Stock (INVA) Company Profile
Name
Innoviva Inc
Sector
Industry
Phone
(650) 238-9600
Address
1350 OLD BAYSHORE HIGHWAY, BURLINGAME
Compare INVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INVA
Innoviva Inc
|
19.51 | 1.45B | 384.03M | 38.65M | 196.35M | 0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Innoviva Inc Stock (INVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Sell |
| Aug-11-25 | Initiated | Oppenheimer | Outperform |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-20-22 | Initiated | Goldman | Neutral |
| Nov-20-17 | Initiated | Deutsche Bank | Hold |
View All
Innoviva Inc Stock (INVA) Latest News
Innoviva, Inc. (INVA) Stock Analysis: Exploring a 67% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Understanding Momentum Shifts in (INVA) - Stock Traders Daily
Innoviva (INVA) price target decreased by 12.36% to 32.90 - MSN
Can Innoviva Inc. stock beat market expectations this quarterStability vs Neutral Overview & support options for steady strides - Улправда
Innoviva, Inc.Common Stock (NQ: INVA - FinancialContent
Volume Recap: Can Innoviva Inc. stock beat market expectations this quarterJuly 2025 Review & Safe Capital Growth Tips - Улправда
Is Innoviva Inc. stock positioned for digital transformationOil Prices & High Return Trade Guides - Улправда
Is Innoviva Inc. stock in correction or buying zoneJuly 2025 Macro Moves & Weekly Setup with ROI Potential - ulpravda.ru
Los Angeles Daily NewsInnoviva, Inc.Common Stock (Nasdaq:INVA) Detailed Stock Data - FinancialContent
Is Innoviva Inc. (HVE) stock good for wealth creationJuly 2025 Big Picture & Real-Time Buy Zone Alerts - ulpravda.ru
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - Investing.com
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out - MarketBeat
Nasdaq Futures Spotlight Innoviva’s Royalty-Based Life Sciences Model - Kalkine Media
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Innoviva, Inc. (INVA) Stock Report: Exploring A 62% Upside Potential - DirectorsTalk Interviews
Will Innoviva Inc. (HVE) stock recover faster than industry2026 world cup usa national team quarterfinals defensive leaders low block defense knockout prediction preview - ulpravda.ru
Synergy Asset Management LLC Invests $1.85 Million in Innoviva, Inc. $INVA - MarketBeat
INVA Stock Price, Forecast & Analysis | INNOVIVA INC (NASDAQ:INVA) - Chartmill
Avoiding Lag: Real-Time Signals in (INVA) Movement - Stock Traders Daily
Innoviva’s Stock Under the Microscope: Is INVA Quietly Setting Up Its Next Move? - AD HOC NEWS
Innoviva joins elite list of stocks with 95-plus composite rating - MSN
Pacer Advisors Inc. Sells 48,889 Shares of Innoviva, Inc. $INVA - Defense World
Scotiabank Initiates Coverage of Innoviva (INVA) with Sector Outperform Recommendation - MSN
Is Innoviva Inc stock in correction or buying zoneJuly 2025 Reactions & Community Trade Idea Sharing Platform - moha.gov.vn
Despite Lower Earnings Than Five Years Ago, Innoviva (NASDAQ:INVA) Investors Are up 65% Since Then - 富途牛牛
Innoviva (INVA): Valuation Check After FDA Approval of First-in-Class NUZOLVENCE Antibiotic - Sahm
Innoviva (NASDAQ:INVA) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Innoviva Inc (NASDAQ:INVA) Nasdaq Composite ETF Therapy Royalties - Kalkine Media
Is Innoviva Inc a good long term investmentMarket Sentiment Report & Small Investment Portfolio - earlytimes.in
December 2026 Options Now Available For Innoviva (INVA) - Nasdaq
How Investors May Respond To Innoviva (INVA) Winning FDA Approval For First-In-Class Gonorrhea Drug - Sahm
H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating - Finviz
Technical Reactions to INVA Trends in Macro Strategies - Stock Traders Daily
Will Innoviva Inc. stock attract ESG investorsTrade Exit Report & Daily Profit Maximizing Trade Tips - Улправда
Will Innoviva Inc. (HVE) stock justify high valuation2025 Volatility Report & Weekly Watchlist for Consistent Profits - Улправда
12 Small Cap Stocks to Buy with Huge Upside Potential - Insider Monkey
Can Innoviva Inc. stock deliver surprise earnings beatMarket Growth Summary & Low Drawdown Momentum Ideas - Улправда
Aug Fed Impact: How Innoviva Inc. (HVE) stock compares with tech leadersInsider Selling & Short-Term High Return Ideas - Улправда
Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Weekly Recap & Daily Stock Trend Reports - Улправда
Is Innoviva Still Attractive Around $20 After Strong Multi Year Share Price Gains? - Yahoo Finance
How Innoviva Inc. stock responds to policy changesQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - DonanımHaber
Why Innoviva Inc. stock is in analyst buy zoneWeekly Risk Summary & Stock Portfolio Risk Control - DonanımHaber
Can Innoviva Inc. stock deliver sustainable ROENew Guidance & Low Risk Entry Point Guides - DonanımHaber
Profit Recap: Can Innoviva Inc. (HVE) stock deliver double digit returnsJuly 2025 Catalysts & Weekly Stock Performance Updates - Улправда
Will Innoviva Inc. stock see PE expansion2025 Performance Recap & Capital Efficiency Focused Ideas - Улправда
Innoviva, Inc. (NASDAQ:INVA) Receives $38.60 Average Target Price from Analysts - Defense World
HC Wainwright & Co. Maintains Innoviva (INVA) Buy Recommendation - Nasdaq
INVA: HC Wainwright & Co. Maintains Buy Rating and Raises Price Target | INVA Stock News - GuruFocus
Innoviva announces Lancet publication of 'positive' Zoliflodacin Phase 3 data - MSN
Innoviva Inc Stock (INVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.73%
2.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):